In early December 2025, Recursion Pharmaceuticals released clinical data from the TUPELO Phase 1b/2 trial of REC-4881, providing fresh insight into the candidate’s safety and efficacy profile. This ...

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.45. LONDON — In the year-plus since Najat Khan joined the AI-focused drug ...

Billy Edmonson voted for President Donald Trump in 2024 because of his stances on border security, gun rights and the economy. One year after casting his ballot, Edmonson is finding it difficult to ...

Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. An announcement from Recursion ...

We recently published 12 Best Healthcare Stocks to Buy Under $30. Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the best healthcare stocks. Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is a ...

I have approximately the time it takes for I’m With Her to pile into a sprinter van backstage at Colorado’s Telluride Bluegrass Festival and drive to their late-night show at the nearby Sheridan Opera ...

Imagine this: you’re in a meeting, tasked with explaining a critical concept to your team. The stakes are high, and all eyes are on you. You start talking, but halfway through, you notice blank stares ...

This week, I had to make one of the most difficult decisions of my career: saying goodbye to 20% of the team at Recursion. The process was extraordinarily painful, and the costs were heartbreakingly ...

Evidently in the mood for some spring cleaning, Salt Lake City’s Recursion is clearing out a chunk of its pipeline as it narrows its focus on R&D in oncology and rare diseases. The move comes roughly ...

Congress is back in D.C. with plans to move forward on a budget framework that could include cuts to Medicaid. About one in three people with disabilities is enrolled in the program which helps them ...